2012
DOI: 10.2174/0929867311320020004
|View full text |Cite
|
Sign up to set email alerts
|

Steroid Receptor Ligands for Breast Cancer Targeting: An Insight into Their Potential Role As Pet Imaging Agents

Abstract: The design and development of radiolabelled steroid derivatives has been an important area of research due to their wellknown value in breast cancer targeting. The estrogen receptor (ER) and progesterone receptor (PR) are important biomarkers in the diagnosis, prognosis and follow-up of the therapeutic response of breast tumours. Thus, several radioligands based on estrogens and progestins have been proposed for targeted functional ER imaging. The aim of this review is to survey and analyze the developments in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2014
2014

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 234 publications
(374 reference statements)
0
1
0
Order By: Relevance
“…For decades, the steroid receptors, estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR), have been the targets of diagnostic molecular imaging in breast and prostate cancers using positron emission tomography (PET), for the purpose of staging disease and monitoring tumor drug exposure and response to therapies . Among the fluorine‐18‐labeled steroid receptor ligands, 16 α ‐[ 18 F]fluoroestradiol ([ 18 F]FES) has been studied extensively as an ER tracer in breast cancer; 16 β ‐[ 18 F]fluoro‐5 α ‐dihydrotestosterone ([ 18 F]FDHT), an AR tracer, has also been found useful for imaging prostate cancer in both the research and clinical settings .…”
Section: Introductionmentioning
confidence: 99%
“…For decades, the steroid receptors, estrogen receptor (ER), progesterone receptor (PR), and androgen receptor (AR), have been the targets of diagnostic molecular imaging in breast and prostate cancers using positron emission tomography (PET), for the purpose of staging disease and monitoring tumor drug exposure and response to therapies . Among the fluorine‐18‐labeled steroid receptor ligands, 16 α ‐[ 18 F]fluoroestradiol ([ 18 F]FES) has been studied extensively as an ER tracer in breast cancer; 16 β ‐[ 18 F]fluoro‐5 α ‐dihydrotestosterone ([ 18 F]FDHT), an AR tracer, has also been found useful for imaging prostate cancer in both the research and clinical settings .…”
Section: Introductionmentioning
confidence: 99%